In stroke models, adult progenitor cell therapy leads to decreased tissue levels of pro-inflammatory cytokines such as interleukin-1 alpha (IL1α), interleukin-1 beta (IL1β), and TNF-α and interleukin-6 (IL-6) and increased levels of anti-inflammatory cytokine such as IL-10 [27, 28]. Here, IL1A is linked to Stroke.